Translational drugs targeting cancer stem cells in triple-negative breast cancer

针对三阴性乳腺癌癌症干细胞的转化药物

阅读:2

Abstract

Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is unresponsive to targeted therapy and is associated with a high degree of malignancy, a high propensity for metastasis, high recurrence rates, and poor prognosis. In the modern concept of cancer biology, a subset of cancer cells known as tumor-initiating cells or cancer stem cells (CSCs) are defined as essential for the development and dissemination of cancer. These are a population of highly tumorigenic and self-renewing pluripotent cells that are inherently associated to the initiation, dissemination, relapse, and development of drug resistance. Specifically, some cell signaling pathways may affect the ability of CSCs to self-renew, differentiate, proliferate, and survive. To guide future research, in this review, we address compounds that target cell signaling and eliminate TNBC stem cells. Potential translational inhibitors of the Hedgehog, nuclear factor κB (NF-κB), Wnt, Notch, Hippo, TGF-β, JAK/STAT, and PI3K/AKT/mTOR cell signaling pathways are discussed, with a focus on TNBC stem cell eradication.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。